Treatment for Adolescents With Depression Study (TADS)

Slides:



Advertisements
Similar presentations
Effectiveness & Cost-Effectiveness of Collaborative Care Depression Treatment in Veterans who screen positive for PTSD Domin Chan, MHS, PhC Northwest HSRD.
Advertisements

1  Assessment of ADHD › Four 15 minute office visits  Treatment is NOT an emergency › Take your time › Ensure diagnosis is correct 1
Staying well after depression (SWAD) CI Professor Mark Williams PI Professor Ian Russell Sholto Radford Research Officer
Pharmacologic Treatments. 2 Cognitive Behavioural Therapy (CBT) Psychosocial Interventions.
Is Caregiver Depression Associated with Children’s ADHD Symptoms and Overall Functioning? Randi Scott SUMR Final Presentation August 07, 2008.
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Aftercare Attendance Partially Moderated by History of Physical Abuse and Gender Louise F. Haynes 1 ; Amy E. Herrin 1 ; Rickey E. Carter 1 ; Sudie E. Back.
1 Recent Observational Studies of Antidepressants (ADs) and Suicidal Behavior Diane K. Wysowski, Ph.D. Office of Drug Safety FDA.
Depression in Adolescence. Topics To Be Covered n What is depression? n Prevalence in adolescence –Gender differences –Course of depression n What causes.
Mood Disorders. Level of analysis Depression as a symptom Depression as a syndrome Depression as a disorder.
Mental Health from a Public Health Perspective Professor Carol S. Aneshensel Department of Community Health Sciences 10/12/09.
Setting the Standard for Psychiatric & Addiction Services Inpatient Treatment for Adolescents Jeanne Resendez Referral Development Manager.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Depressive Disorders.
Depression Measures Health Disparities Collaborative 2005.
OCD Facts *All facts obtained through DynaMed Database or ocdeducationstation.org.
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
Youth Empowerment Services (YES) A Medicaid Waiver Program for Children with Severe Emotional Disturbances Clinical Eligibility Determination Texas Department.
Treating Depression in the Elderly A Multi-disciplinary Approach 12/11/2003.
Continuity Clinic Depression. Continuity Clinic Objectives.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
Mood Disorders. Major Depressive Disorder  Five or more symptoms present for two weeks or more:  Disturbed Mood  depressed mood  anhedonia (reduced.
Depression in Adolescents and Young Adults: current best practice David Hartman Psychiatrist Child, Adolescent and Young Adult Service Institute of Mental.
Suicide Risk and Antidepressants. Background 1990 Case reports 2003 Advisory: pediatric patients 2004 Warning: children and adolescents 2005 Advisory:
Chapter 7 Mood Disorders and Suicide
 Major depressive disorder (MDD) is a debilitating condition that has been increasingly recognized among youth  Prevalence of current or recent depression.
1 Statistical Perspective Acamprosate Experience Sue-Jane Wang, Ph.D. Statistics Leader Alcoholism Treatment Clinical Trials May 10, 2002 Drug Abuse Advisory.
RESPONSE TO ANTIDEPRESSANT MEDICATION, COGNITIVE BEHAVIOR THERAPY AND PLACEBO IN CHRONIC TENSION-TYPE HEADACHE VARIES WITH PSYCHIATRIC COMORBIDITY & HEADACHE.
Case Finding and Care in Suicide: Children, Adolescents and Adults Chapter 36.
Pediatric Psychopharmacology National Institute of Mental Health.
THE IMPACT OF ANTI-DEPRESSANTS AND COGNITIVE THERAPY ON PANIC DISORDER Christopher Cannizzaro Rowan University Abnormal Psychology.
Study Design for a Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit.
Internet therapy for depression in Primary Care Marie Kivi licensed Psychologist / PhD-student Department of Psychology, University of Gothenburg, Sweden.
Adolescent Depression Treatment Mary Mills BSN, RN.
 Copy: few empirical studies compared to other treatments  Eysenck- reviewed 2 studies, incorporating waiting list controls, which showed that 66% of.
ADOLESCENTS IN CRISIS: WHEN TO ADMIT FOR SELF-HARM OR AGGRESSIVE BEHAVIOR Kristin Calvert.
Jeffrey Jonas, MD Vice President CNS - Forest Research Institute Citalopram and Escitalopram Pediatric Safety Data.
Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective.
Retrospective evaluation of ASAM criteria in adolescents receiving weekly outpatient treatment for co-occurring psychiatric and substance use disorders.
Raymond F. Anton, MD for The COMBINE Study Research Group
Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence Jill A. Morris, PA-S.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
National Drug Abuse Treatment Clinical Trials Network National Drug Abuse Treatment Clinical Trials Network A Randomized Controlled Trial of OROS-MPH +
Chapter 10: Depressive Disorders in Adolescents Megan Jeffreys V. Robin Weersing.
FDA Hearing on Suicide and Antidepressants Presentation by Charles F. Reynolds, III, MD UPMC Professor of Geriatric Psychiatry University of Pittsburgh.
Ron Beasley, PharmD Candidate Preceptor: Soheyla Mahdavian, PharmD
1 Characteristics of Pediatric Antidepressant Trials Gregory M. Dubitsky, MD Division of Neuropharmacological Drug Products FDA.
RNSG 1163 Summer Qe8cR4Jl10.
Sertraline Use in Pediatric Population: A Risk Benefit Discussion Steven J. Romano, MD September 13, 2004 Steven J. Romano, MD September 13, 2004 Joint.
STAR*D Objectives Compare relative efficacy of different treatment options –Goal is REMISSION, not just “response” –Less than half of patients with depression.
BIPOLAR DISEASE IN CHILDREN AND YOUNG ADOLESCENTS By Priya Modi and Kojo Koranteng and Aarushi Sharma.
Journal of the American Medical Association (JAMA), 2004, 291:
Effectiveness of Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Adolescents with Depression Megan Boose, PA-S Evidence Based.
Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.
Integrating Tobacco Prevention Strategies into Behavioral Parent Training for Adolescents with ADHD Rosalie Corona, Ph.D. Associate Professor of Psychology.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
PSYC 377.  Use the following link to access Oxford Health: Children and Family Division en-and-families.
Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Catherine Lennox EDPS 635 Summer 2016
Depression: How to diagnose and how to start treatment
3 July 2017 Working with students with Personality Disorder and Risk: Developing the Student Health Emotion Regulation Pathway (SHERPA) Dr Ian Barkataki.
Pharmacological and Behavioral
Alcohol, Other Drugs, and Health: Current Evidence
Bruce Waslick, MD Medical Director UMass / Baystate MCPAP Team
Behavioral Health Overview
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Scientific Update.
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
Presentation transcript:

Treatment for Adolescents With Depression Study (TADS)

Fluoxetine, Cognitive Behavioral Therapy, and Their Combination for Adolescents With Depression Treatment for Adolescents With Depression Study (TADS) Team JAMA 2004: Vol 292, No. 7

TADS A randomized controlled trial funded by the National Institute of Mental Health Conducted at 13 academic and community centers in the United States To evaluate the effectiveness of treatments for adolescents with MDD

Participants 429 patients Age years (mean age 15 years) Primary diagnosis of major depressive disorder (DSM-IV)

Inclusion Criteria Outpatient CDRS ≥ 45 IQ ≥ 80 Not taking antidepressants Depressive mood in at least 2 contexts for at least 6 weeks prior to consent

Exclusion criteria Bipolar disorder Severe conduct disorder Substance abuse PDD Thought disorder Concurrent psychotropic medications Failed 2 SSRIs or CBT

Exclusion criteria Dangerousness to self or others Had been hospitalized for dangerousness within 3 months Suicidal attempt within 6 months Active plan of suicide Suicidal ideation with disorganized family

Participants Moderate to severe symptoms Average depressive episode duration - 72 weeks 27% had at least minimal suicidal ideation at baseline

Randomization To 1 of 4 treatments for 12 weeks 1. Fluoxetine alone 2. CBT alone 3. Fluoxetine with CBT 4. Placebo

Randomization Blinding Independent evaluators

Fluoxetine 6 medication visits x minutes Dosage adjusted Starting dose 10 mg/d Optimum 20 mg/d Maximum 40 mg/d Mean highest dose 30 mg/d

CBT 15 sessions over 12 weeks x minutes Psychoeducation Mood monitoring Increasing pleasant activities Social problem solving Cognitive restructuring Parent and family sessions

Outcome Assessment Children’s Depression Rating Scale-Revised (CDRS-R) CGI improvement score (much improved or very much improved) Assessed at baseline, week 6, and week12

Outcome Assessment Reynolds Adolescent Depression Scale (RADS) Suicidal Ideation Questionnaire-Junior High School Version (SIQ-Jr) All measures reported acceptable psychometric properties

Harm-Related Adverse Event Harm to self; e.g. cutting Worsening of suicidal ideation Suicidal attempt Harm to others

Suicide-Related Adverse Event Worsening suicidal ideation Suicidal attempt

Results Combination of fluoxetine with CBT was significantly superior to placebo fluoxetine alone CBT alone

Results Fluoxetine alone was superior to placebo CBT alone was not superior to placebo Fluoxetine alone was significantly better than CBT alone

Response Rate Based On CGI 71% in the fluoxetine with CBT 61% in the fluoxetine alone 43% in the CBT alone 35% in the placebo

Results Effect size (CDRS-R) Effect size (CGI) NNT Fluoxetine + CBT Fluoxetine alone CBT alone

Results “Combination of fluoxetine with CBT is better than fluoxetine alone, which is better than CBT alone, which is equal to placebo”

Suicidal Behavior in Children Receiving SSRIs Suicidal ideation decreased in all of the treatment groups 6% of the patients experienced a suicide- related event with no statistically significant difference among the 4 treatment groups Seven patients made a suicide attempt and there were no completed suicides

Suicidal Behavior in Children Receiving SSRIs Harm-related adverse events: increased risk (odds ratio = 2.19) for patients receiving fluoxetine compared with those who were not The odds ratio was higher for fluoxetine alone compared with fluoxetine with CBT. Protective effect for CBT for suicidal ideation

Summary Combination treatment with fluoxetine and CBT shows highest efficacy CBT is a protective factor for suicide in adolescents receiving fluoxetine